© 2024 Corcept Therapeutics, Incorporated
Featured
Stories
All Stories
Honoring Dr. LaSalle D. Leffall Jr.
Article:
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism
Press Release: Dec 30, 2024
Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism
Press Release: Dec 16, 2024
Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes
Press Release: Dec 14, 2024
‘Constantly stressed out’: A woman’s battle with excess cortisol
Article:
Honoring Ildaura Murillo-Rohde
Article:
Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes
Article:
Navigating Hypercortisolism: Deile’s Story
Article:
Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions
Press Release: Jun 24, 2024